Zylox-Tonbridge Medical Technology (HKEX: 2190) and Beijing-based private equity firm GL Capital announced Friday that they have conditionally agreed to subscribe for approximately 16.73% of LifeTech Scientific Corporation (HKEX: 1302), paying HK$1.482 billion (approximately $189 million USD; exchange rate as of late October 2026) through a special-purpose vehicle they named GL Lighthouse Two Investment Limited. The deal values LifeTech shares at HK$1.60 (approximately $0.20 USD) apiece. More significantly, both buyers have made explicit in the transaction announcement their intent to pursue a full merger — a step that would create China’s most broadly diversified listed cardiovascular interventional device company.
The announcement was filed with the Hong Kong Exchange on November 6, 2026. Upon completion of the subscription, GL Lighthouse Two Investment Limited would become LifeTech’s largest single shareholder.
To understand why two profitable, fast-growing Chinese medtech companies are merging when both appear to be doing well on their own, you have to understand what China’s volume-based procurement (VBP) system has done to their industry over the past five years.
China’s National Healthcare Security Administration (NHSA) runs a nationalized tender program in which hospitals agree to buy defined volumes of medical devices in exchange for manufacturers competing to offer the lowest unit price. The model was borrowed from China’s pharmaceutical sector and applied to high-value devices starting in 2020. The results have been dramatic.
Coronary stents — once a highly profitable product category for every major manufacturer operating in China — saw prices fall more than 90% after the first national device VBP round in 2021. The neurovascular coil category, which Medtronic competes in, prompted Medtronic’s CEO to tell investors in 2023 that the VBP impact was “largely behind us” after multiple quarters of pressure.
Peripheral vascular stents — a core product category for both Zylox-Tonbridge and LifeTech — were swept into Batch 5 of the national VBP program in December 2024, with price reductions of more than 80% documented across the included categories.
A company that sells peripheral vascular stents for HK$10,000 (approximately $1,275 USD) per unit under the old pricing model and must now sell the equivalent product for HK$1,500–2,000 (approximately $191–$255 USD) faces a stark choice: defend margins through scale and product breadth, exit the category, or find a merger partner whose product portfolio offsets the compressed segments.
Zylox-Tonbridge and LifeTech have chosen the third option — and they are not alone in seeing it this way. MicroPort Scientific (HKEX: 853) announced a roughly $680 million strategic merger of its CardioFlow structural heart and cardiac rhythm management (CRM) divisions in October 2025, restructuring two previously separate business lines into a single operating entity for exactly the same reason.
The strategic logic of pairing Zylox-Tonbridge with LifeTech Scientific becomes clear when you map their product portfolios against each other.
Zylox-Tonbridge is primarily a neurovascular and peripheral vascular company. Its flagship product, the Kylin Flow Diverter, is a dense-mesh braided nitinol device deployed across the neck of a cerebral aneurysm: rather than packing the aneurysm sac with coils, the Kylin redirects blood flow away from the sac, promoting clot formation and eventual aneurysm occlusion over three to six months. The technique, known as flow diversion, has become the preferred approach for wide-neck and large cerebral aneurysms because it does not require the precise catheter navigation that coil embolization demands. The company also makes the SilverSnake peripheral stent for arterial disease in the legs. Its H1 2026 revenue totaled RMB 632 million (approximately $94.6 million USD), up 31.1% year-over-year, with net profit of RMB 179 million (approximately $26.8 million USD), up 47.8%.
LifeTech Scientific operates at the other end of the cardiovascular spectrum. Its largest revenue segment is peripheral vascular disease (PVD), dominated by aortic stent grafts — fabric-covered metal scaffolds that are threaded via catheter into the aorta and deployed to exclude an aneurysm sac or seal a dissection without the mortality risk of open surgery. LifeTech’s Ankura Pro system covers thoracic aortic disease; the Longuette handles aortic branch anatomy; the Yuranos series targets the abdominal aorta. Stent graft sales grew 19.9% in fiscal year 2025, driving PVD segment revenue to RMB 844.6 million (approximately $126.5 million USD), up 12.4% — the strongest segment in the company’s portfolio.
LifeTech’s second major segment is structural heart disease (SHD), encompassing its LAmbre Left Atrial Appendage (LAA) occluder and three generations of congenital heart defect occluders. The LAA is a small pouch off the left atrium where up to 90% of strokes originate in patients with atrial fibrillation; LifeTech’s device seals this pouch percutaneously, offering stroke prevention as an alternative to lifelong anticoagulant therapy. This segment posted RMB 511.7 million (approximately $76.6 million USD) in FY2025 revenue, down 3.0% year-over-year — the VBP effect visible in the numbers.
LifeTech’s total FY2025 revenue came to RMB 1,369.8 million (approximately $205 million USD), up 5.1%, with gross margin of 74.4% and adjusted net profit of RMB 353.4 million (approximately $52.9 million USD), up 24.9%. The company invests heavily in R&D: RMB 329.0 million (approximately $49.3 million USD), equal to 24% of annual revenue. Europe has become LifeTech’s fastest-growing international market, up 25.9% in FY2025 and accounting for 12.1% of total revenue.
Combined, the two companies would cover a continuous cardiovascular intervention spectrum: from cerebral aneurysm (Zylox’s Kylin) through peripheral arterial disease (both companies’ vascular stents) through thoracic and abdominal aortic disease (LifeTech’s stent grafts) through structural cardiac defects and atrial fibrillation stroke prevention (LifeTech’s occluders) — with Zylox separately developing a transcatheter aortic valve replacement (TAVR) product that would eventually add valvular heart disease to the platform.
Zylox-Tonbridge’s co-founder, chairman, and CEO, Dr. Jonathon Zhong Zhao, holds a doctorate from The Johns Hopkins University School of Medicine. Before launching Zylox-Tonbridge in November 2012, he spent nine years as a principal scientist and research fellow at Cordis Corporation — Johnson & Johnson’s interventional cardiology division, headquartered in Miami Lakes, Florida — from 2002 to 2011.
Cordis was itself a product of exactly the kind of consolidation wave now reshaping China’s device market. The company’s roots trace to the 1990s, when the introduction of Medicare’s prospective payment system (DRG system) in the United States forced hospital procurement departments to demand price concessions from device manufacturers. The resulting margin pressure triggered a decade of mergers and acquisitions — the consolidation that produced the modern US medtech landscape and the large-platform companies that dominate it today. J&J acquired Cordis in 1996 for approximately $1.8 billion, precisely to assemble breadth of cardiovascular product coverage as a defense against pricing pressure from procurement-focused hospital systems.
Zhao spent nearly a decade inside that company before returning to China and building Zylox-Tonbridge from scratch. The Zylox+LifeTech merger strategy maps almost exactly onto the platform-assembly logic J&J used to build Cordis’s breadth — applied now to China’s VBP-driven pricing environment instead of the DRG-driven environment Zhao observed from Miami Lakes.
He previously served as an independent director at Avinger, Inc. (Nasdaq: AVGR), a US-listed company developing image-guided peripheral arterial disease treatment — a governance role that kept him in direct contact with US device regulatory and market conditions while he built Zylox-Tonbridge.
GL Capital, the Beijing-based healthcare private equity firm that takes the other 40% of GL Lighthouse Two Investment Limited, was founded in 2010 by Jeffrey Li, who previously served as Country President of Novartis China and began his investment career with the Pritzker family in 1993. The firm focuses exclusively on Chinese healthcare companies and targets buyouts of leading positions.
GL Capital’s latest flagship fund held a $385 million first close, and its fourth dedicated healthcare PE fund has raised more than $162 million. The firm has previously led a $290 million investment in Sangon Biotech and closed a $240 million SciClone Pharmaceuticals continuation vehicle backed by the Abu Dhabi Investment Authority (ADIA). Its partnership with Zylox-Tonbridge in the LifeTech deal follows a pattern: GL Capital has repeatedly backed Chinese healthcare companies in scale-up transactions across the HKEX-listed portfolio.
The 16.7% stake conditionally subscribed through GL Lighthouse Two Investment Limited does not constitute a controlling position under HKEX or Chinese corporate law, and would not automatically trigger mandatory general offer obligations or antitrust filings in most jurisdictions at this threshold. However, the deal announcement’s explicit statement of full-merger intent signals that both parties expect to increase their position materially over time.
A full merger of two HKEX-listed companies of this scale would require:
No timeline for the full merger has been specified in the available public announcement.
Any discussion of Chinese medical device companies operating at scale — particularly in devices that collect patient health data, connect to hospital systems, or use remote monitoring platforms — requires explicit understanding of the Chinese legal framework governing that data.
China’s National Intelligence Law (2017), Article 7 states: “All organizations and citizens shall support, assist, and cooperate with national intelligence work in accordance with law, and shall protect national intelligence work secrets they are aware of.”
This requirement applies to all companies domiciled in China, regardless of their international stock listing, the nationality of their shareholders, or the physical location of their data servers. It is not a risk to be weighed against product quality or price; it is a fixed legal condition of corporate operation under Chinese jurisdiction.
China’s Data Security Law (2021) requires that data processing activities comply with government data localization mandates and that organizations cooperate with government data access requests.
China’s Cybersecurity Law (2017), Article 28 requires network operators to “provide technical support and assistance to public security organs and national security organs that are safeguarding national security or investigating criminal activities.”
For the combined Zylox+LifeTech entity — which would manufacture implantable cardiovascular devices used in patients across China, Europe, and Southeast Asia — this legal framework means that any patient-linked data processed by company systems in China is subject to these obligations. No independent security audit of either company’s patient data handling practices has been publicly released.
Hospitals and healthcare system procurement officers outside China evaluating these devices can take practical steps: requiring contractual data localization clauses, mandating on-premises data storage for patient-linked information, and requesting documented data flow maps. These measures limit but do not eliminate the structural legal risk created by Chinese national law.
This is not a unique condition of Zylox-Tonbridge or LifeTech specifically — it applies to every Chinese-domiciled medtech company manufacturing connected or data-generating devices. It is, however, a material factor that belongs in every procurement decision and investor assessment involving this transaction.
Exchange rates as of late October 2026 (source: Federal Reserve Bank of St. Louis FRED series DEXHKUS for HKD/USD; Pound Sterling Live USD-CNY 2026 history for CNY/USD); conversions are approximate and reflect mid-market rates, not transaction prices.
Zylox-Tonbridge (HKEX: 2190) is a Hangzhou-based Chinese medical device company specializing in neurovascular and peripheral vascular interventional products. Its flagship product, the Kylin Flow Diverter, is used to treat wide-neck cerebral aneurysms by redirecting blood flow away from the aneurysm rather than packing it with coils. The company posted RMB 632 million revenue (approximately $94.6 million USD) in H1 2026, up 31.1% year-over-year.
LifeTech Scientific (HKEX: 1302) is a Chinese cardiovascular device company whose two main product lines are aortic stent grafts (used to treat thoracic and abdominal aortic aneurysms and dissections) and structural heart disease devices (including left atrial appendage occluders used to reduce stroke risk in atrial fibrillation patients). Its FY2025 revenue was RMB 1,369.8 million (approximately $205 million USD).
VBP is China’s national government tender program in which hospitals commit to purchasing specified volumes of medical devices in exchange for manufacturers offering substantially reduced prices. Coronary stent prices fell more than 90% under the 2021 national round; peripheral vascular stent prices fell more than 80% under Batch 5 (December 2024). The program compresses the margins that sustain medtech R&D and sales infrastructure, creating strong financial pressure to consolidate into broader platforms that can absorb pricing concessions across a diverse product mix.
An aortic stent graft is a fabric tube supported by a nitinol or stainless-steel mesh skeleton. It is delivered through a catheter inserted via the femoral artery and deployed inside the diseased segment of the aorta — either the thoracic aorta (TEVAR procedure) or the abdominal aorta (EVAR procedure). Once deployed, it seals the aneurysm sac or dissection tear from arterial blood pressure, preventing rupture without the need for open surgical clamping of the aorta. Recovery from EVAR is typically one to two hospital nights. The first successful EVAR was performed by Juan Parodi in Buenos Aires in 1990; it overtook open surgery as the standard AAA repair technique by 2003.
The left atrial appendage is a small muscular pouch off the left atrium of the heart. In patients with atrial fibrillation, blood pooling in the LAA is responsible for approximately 90% of the thrombi that cause AF-related strokes. A percutaneous LAA occlusion device — such as LifeTech’s LAmbre LAA closure system — is threaded transseptally (through the septum separating the heart’s two atria) and deployed to seal the LAA opening, preventing clot formation as an alternative to lifelong anticoagulant medication.
GL Capital is a Beijing-based healthcare-focused private equity firm founded in 2010 by Jeffrey Li, a former Novartis China country president. It manages multiple HKEX-focused healthcare funds and has previously invested in Sangon Biotech ($290 million), SciClone Pharmaceuticals (a $240 million continuation vehicle), and UK-listed healthtech platforms. Its latest flagship fund held a $385 million first close.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
About the Author
